Talking With Patients and Care Partners About Treatment Goals and Challenges in Early-Stage Alzheimer Disease
In this webcast about early-stage Alzheimer disease, Drs Burke and Apostolova highlight important conversations to have with patients and their care partners on topics such as diet, exercise, driving, and plans for the later stage of illness.
Alzheimer disease (AD) requires timely diagnosis and treatment initiation as early as possible to delay further loss of functioning. Clinicians must attempt to answer patients’ and care partners’ questions about treatment goals and expected challenges. In this webcast, Drs Burke and Apostolova address topics critical to the care of patients with early-stage AD. They highlight barriers to diagnosis, describe genetic risk factors, and emphasize the role of neuropsychologic testing. Drs Burke and Apostolova agree that, although current medications slow symptom progression associated with AD, emerging therapies offer hope for disease modification. These experts also talk about important conversations to have with patients and their care partners, such as about diet, exercise, driving, and plans for the later stage of illness.
From the Series: Diagnosis of Early-Stage Alzheimer Disease and How Emerging Treatments May Address Unmet Needs
To cite: Burke AD, Apostolova L. Talking with patients and care partners about treatment goals and challenges in early-stage Alzheimer disease. J Clin Psychiatry. 2021;82(3):BG20044WC2C.
To share: https://doi.org/10.4088/JCP.BG20044WC2C
© Copyright 2021 Physicians Postgraduate Press, Inc.
HCPs who specialize in treating Alzheimer disease, including neurologists, geriatric psychiatrists, and neurology NPs and PAs
Discuss treatment goals and challenges with patients who have early-stage Alzheimer disease and their care partners
Supported by an educational grant from Biogen.
After completing this educational activity, you should be able to:
- Discuss treatment goals and challenges with patients who have early-stage Alzheimer disease and their care partners
Release, Review, and Expiration Dates
This brief report activity was published in April 2021 and is eligible for AMA PRA Category 1 Credit™ through April 30, 2023. The latest review of this material was March 2021.
Statement of Need and Purpose
Clinicians are not providing a diagnosis to over half of individuals who meet criteria for Alzheimer disease (AD) and other dementias. When they do give a diagnosis, clinicians are often not effectively communicating with patients and care partners regarding the illness and next steps. Additionally, prompt treatment initiation does not occur in a substantial number of patients newly diagnosed with AD. Clinicians need education on early recognition of AD using a stepwise process that includes patient observation, informant report, use of assessment tools, and additional testing when appropriate. They also need guidance for sharing the diagnosis of AD along with education and next steps, including support services. Clinicians need awareness about addressing the shortcomings of current treatments with patients and families. Although current therapies are not disease modifying, emerging agents may offer new hope. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on Alzheimer disease.
Disclosure of Off-Label Usage
The chair has determined that, to the best of her knowledge, aducanumab* and gantenerumab are not approved by the US Food and Drug Administration for the treatment of Alzheimer’s disease.
*Note: On June 7, 2021, after publication of this activity, the FDA approved aducanumab for the treatment of mild cognitive impairment or mild Alzheimer disease.
The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
This activity is derived from the teleconference series “Diagnosis of Early-Stage Alzheimer Disease and How Emerging Treatments May Address Unmet Needs,” which was held in August and October 2020 and supported by an educational grant from Biogen. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.
Anna D. Burke, MD
Barrow Neurological Institute, Phoenix, AZ
Liana Apostolova, MD, MSc
Indiana University School of Medicine, Indianapolis
The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The Accreditation Council for Continuing Medical Education (ACCME) defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure is as follows:
Liana Apostolova, MD, MSc, is a consultant and a member of the speakers/advisory board for Biogen; has received grant/research support from AVID Radiopharmaceuticals and Life Molecular Imaging; and is a stock shareholder of Semiring.
The Chair for this activity, Anna D. Burke, MD, has no personal affiliations or financial relationships with any commercial interest to disclose relative to the activity.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation